TargetBeta
RET
ret proto-oncogene · also PTC, CDHF12, RET51, CDHR16 · Cadherin related
7 programs in company-led studies act on RET, from 7 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| selpercatinibrule | Eli Lilly | phase 4 | 197 running | CCDC6, KIF5B | NCIt |
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, TEK | ChEMBL |
| pralsetinibrule | Hoffmann-La Roche | phase 4 | 73 running | CCDC6, KIF5B | NCIt |
| quizartinibrule | Daiichi Sankyo | phase 3 | 225 running | CSF1R, FLT3, KIT, PDGFRA, PDGFRB | ChEMBL |
| RET Inhibitor HS-10365 | Hansoh Pharmaceutical Group | phase 2 | 33 running | – | the company's pipeline |
| TRK/RET Inhibitor ND-003rule | Shenzhen NewDEL Biotech | phase 2 | 33 running | – | NCIt |
| RET Inhibitor FHND5071 | Sino Biopharmaceutical | phase 1 | 10 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Carcinoma, Medullary, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Colorectal Neoplasms, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Neoplasms, 1 program
- Pancreatic Neoplasms, 1 program
- Renal Insufficiency, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 30, 2026pralsetinib · Hoffmann-La Roche · phase 4 · NCT04302025
- May 1, 2027quizartinib · Daiichi Sankyo · phase 3 · NCT03793478
- Aug 31, 2027RET Inhibitor HS-10365 · Hansoh Pharmaceutical Group · phase 2 · NCT06147570
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
- Jun 2028TRK/RET Inhibitor ND-003 · Shenzhen NewDEL Biotech · phase 2 · NCT06169579
- Oct 2029selpercatinib · Eli Lilly · phase 4 · NCT07822880
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.